NCT07192432View on ClinicalTrials.gov

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

September 30, 2033

Study Completion Date

October 31, 2033

Conditions
HER2 Expressing Solid Tumors
Interventions
GENETIC

Dose Level 1, VNX-202

Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion

GENETIC

Dose Level 2, VNX-202

Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion

GENETIC

Dose Level 3, VNX-202

Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion

GENETIC

Dose Level 4, VNX-202

Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion

Trial Locations (2)

37203

RECRUITING

SCRI Oncology Partners, Nashville

80218

RECRUITING

SCRI Denver DDU at HealthOne, Denver

All Listed Sponsors
lead

Vironexis Biotherapeutics Inc.

INDUSTRY

NCT07192432 - Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Biotech Hunter | Biotech Hunter